MannKind (FRA:NNFN) Long-Term Debt : €224.6 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is MannKind Long-Term Debt?

MannKind's Long-Term Debt for the quarter that ended in Mar. 2024 was €224.6 Mil.

MannKind's quarterly Long-Term Debt declined from Sep. 2023 (€237.3 Mil) to Dec. 2023 (€228.1 Mil) and declined from Dec. 2023 (€228.1 Mil) to Mar. 2024 (€224.6 Mil).

MannKind's annual Long-Term Debt increased from Dec. 2021 (€248.9 Mil) to Dec. 2022 (€258.2 Mil) but then declined from Dec. 2022 (€258.2 Mil) to Dec. 2023 (€228.1 Mil).

MannKind Long-Term Debt Historical Data

The historical data trend for MannKind's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Long-Term Debt Chart

MannKind Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

102.48

97.14

248.86

258.18

228.06

MannKind Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															244.98	237.92	237.28	228.06	224.62

MannKind (FRA:NNFN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

MannKind Long-Term Debt Related Terms

Thank you for viewing the detailed overview of MannKind's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MannKind (FRA:NNFN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (FRA:NNFN) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

MNKD:USA

Address

1 Casper Street, Danbury, CT, USA, 06810

Website

https://www.mannkindcorp.com

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind (FRA:NNFN) Headlines

No Headlines